Replies to post #105031 on Biotech Values

[DewDiligence]

Cladribine doesn't win on efficacy, safety or convenience. I'm not sure where the market is. Second and third-line salvage therapy, I suppose.

Cladribine’s best shot is in the second-line needle-phobic setting :- )